JCAR-014 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JCAR-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JCAR-014 is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin’s lymphoma such as indolent NHL, mantle cell lymphoma, lymphoblastic leukemia and relapsed acute lymphoblastic lymphoma. The therapeutic candidate is administered intravenously. The therapy comprises of an autologous T-lymphocytes genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19 along with 4-1BB. The therapy is developed based on the CAR (chimeric antigen receptor) and TCR (T cell receptors) technology platforms.
It was also under development for diffuse large B-cell lymphoma (DLBCL), b-cell acute lymphoblastic leukemia, primary mediastinal large b-cell lymphoma.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
For a complete picture of JCAR-014’s drug-specific PTSR and LoA scores, buy the report here.